Դանիա -
դանիերեն -
Lægemiddelstyrelsen (Danish Medicines Agency)
hydrocortison "activase" 20 mg tabletter
activase pharmaceuticals limited - hydrocortison - tabletter - 20 mg
Դանիա -
դանիերեն -
Lægemiddelstyrelsen (Danish Medicines Agency)
nebivolol "glenmark" 10 mg tabletter
glenmark arzneimittel gmbh - nebivololhydrochlorid - tabletter - 10 mg
Դանիա -
դանիերեն -
Lægemiddelstyrelsen (Danish Medicines Agency)
omeprazol "orion" 10 mg enterokapsler, hårde
orion corporation - omeprazol - enterokapsler, hårde - 10 mg
Դանիա -
դանիերեն -
Lægemiddelstyrelsen (Danish Medicines Agency)
nebivolol "krka" 5 mg tabletter
krka d.d. novo mesto - nebivololhydrochlorid - tabletter - 5 mg
Եվրոպական Միություն -
դանիերեն -
EMA (European Medicines Agency)
breyanzi
bristol-myers squibb pharma eeig - cd19-directed genetically modified autologous cell-based product consisting of purified cd8+ t-cells (cd8+ cells), cd19-directed genetically modified autologous cell-based product consisting of purified cd4+ t cells (cd4+ cells) - lymphoma, large b-cell, diffuse; lymphoma, follicular; mediastinal neoplasms - antineoplastiske midler - breyanzi is indicated for the treatment of adult patients with diffuse large b-cell lymphoma (dlbcl), high grade b-cell lymphoma (hgbcl), primary mediastinal large b-cell lymphoma (pmbcl) and follicular lymphoma grade 3b (fl3b), who relapsed within 12 months from completion of, or are refractory to, first-line chemoimmunotherapy.
Դանիա -
դանիերեն -
Lægemiddelstyrelsen (Danish Medicines Agency)
nebivolol "accord" 5 mg tabletter
accord healthcare b.v. - nebivololhydrochlorid - tabletter - 5 mg
Դանիա -
դանիերեն -
Lægemiddelstyrelsen (Danish Medicines Agency)
trilafon dekanoat 108,2 mg/ml injektionsvæske, opløsning, i.m.
orifarm a/s - perphenazindecanoat - injektionsvæske, opløsning, i.m. - 108,2 mg/ml
Եվրոպական Միություն -
դանիերեն -
EMA (European Medicines Agency)
plerixafor accord
accord healthcare s.l.u. - plerixafor - multiple myeloma; hematopoietic stem cell transplantation - immunostimulants, - adult patientsplerixafor accord is indicated in combination with granulocyte-colony stimulating factor (g-csf) to enhance mobilisation of haematopoietic stem cells to the peripheral blood for collection and subsequent autologous transplantation in adult patients with lymphoma or multiple myeloma whose cells mobilise poorly (see section 4. paediatric patients (1 to less than 18 years)plerixafor accord is indicated in combination with g-csf to enhance mobilisation of haematopoietic stem cells to the peripheral blood for collection and subsequent autologous transplantation in children with lymphoma or solid malignant tumours, either:- pre-emptively, when circulating stem cell count on the predicted day of collection after adequate mobilization with g-csf (with or without chemotherapy) is expected to be insufficient with regards to desired hematopoietic stem cells yield, or- who previously failed to collect sufficient haematopoietic stem cells (see section 4.